This article is more than 5 years old. Information may no longer be current.

Hepatic arterial infusion with cisplatin improved outcomes in early HCC

Hepatic arterial infusion with high-concentration cisplatin before radical local treatment improved survival among patients with early-stage hepatocellular carcinoma, according to study results.

The analysis included 114 patients with HCC. All patients had a Japan Integrated Staging score of 0 or 1.

Seventy-nine patients received high-concentration cisplatin infused into the whole liver via the proper hepatic artery before radical local treatment. The remaining 35 patients did not receive chemotherapy before radical local treatment.

Patients who received hepatic arterial infusion chemotherapy demonstrated improved cumulative survival at 1 year (97.4% vs. 77.4%), 3 years (87% vs. 69.2%) and 5 years (84.4% vs. 55.3%).

Overall, survival was significantly improved among patients who received hepatic arterial infusion chemotherapy according to the Log-Rank test (P=.023) and Generalized Wilcoxon test (P=.012).

Results of a multivariate analysis indicated hepatic arterial infusion with high-concentration cisplatin was the most significant factor that affected patient survival.

“Whole liver hepatic arterial infusion with high-concentration cisplatin before radical local treatment can improve the prognosis of patients with early-stage HCC,” the researchers concluded.

Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.